IDO in MDS/AML disease progression and its role in resistance to azaci-tidine: a potential new drug target? Veröffentlicht vonbrigittemeiswinkel 9. November 2020 Leisch, M; Greil, R; Pleyer, L. Br J Haematol. 2020 Aug;190(3):314-317. doi: 10.1111/bjh.16710. Epub 2020 May 17. https://pubmed.ncbi.nlm.nih.gov/32419137/